CDNA CareDx, Inc.
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.…
Industry Peers
Diagnostics & ResearchKey Statistics
About CareDx (NASDAQ: CDNA)
›
CareDx (NASDAQ: CDNA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 761 employees.
The shares were at 71.92 USD on 19 November 2026, up 379.1% over 52 weeks. Its 52-week range is 14.72 USD to 90.87 USD: the price is 20.9% below the high and 388.6% above the low.
At a market capitalisation of 3.78B USD, it trades at 30.3 times trailing earnings and 46.0 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a discount of 15% for CDNA.
CareDx reports return on equity of -7.0%, an operating margin of 1.6% and revenue up 39.3% year over year.
It holds more cash than debt, a net cash position of 221.48M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Buy; their mean price target of 94.43 USD is 31.3% above the current price. The next earnings report is expected on 24 February 2027.